

## Favezelimab

Cat. No.:	HY-P99613
CAS No.:	2231068-83-8
Target:	LAG-3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902)<sup>[1][2]</sup>.

### REFERENCES

[1]. Carmen Belli, et al. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies. *Cancers (Basel)*. 2022 Sep 1;14(17):4278.

[2]. Gareth P. Gregory, et al. Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. *Cancer Res (2019) 79 (13\_Supplement): CT106*.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA